Lack of genotoxicity of tamoxifen in human endometrium

Cancer Research

Volumn 56, Issue 7, 1996, Pages 1475-1479

  Carmichael, Paul L ^a   Ugwumadu, Austin H N ^b   Neven, Patrick ^c   Hewer, Alan J ^a   Poon, Grace K ^a   Phillips, David H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

^c Saint Jean Clinic of Brussels   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; DIMETHYL SULFOXIDE; HYDROXYTAMOXIFEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CELL VIABILITY; DNA ADDUCT; DNA DAMAGE; DRUG POTENCY; ENDOMETRIUM; ENZYME METABOLISM; GENOTOXICITY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CULTURE TECHNIQUES; DNA ADDUCTS; DNA DAMAGE; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; RATS; TAMOXIFEN;

EID: 0029978834     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339 1-15,71-85, 1992
2. Gray, R. Tamoxifen how boldly to go where no women have gone before. J Natl. Cancer Inst , 85 1358-1360, 1993.
3. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats Cancer Res., 53: 3919-3924, 1993
4. Han, X., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res , 52. 1360-1363, 1992
5. White, I N H , de Mateis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C , Venitt, S., Hewer, A., and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis (Lond.), 13: 2197-2203, 1992
6. Crofton-Sleigh, C , Doherty, A., Ellard, S , Parry, E. M., and Venitt, S. Micronucleus assays using cytochalasin-blocked MCL-5 cells, a proprietary human cell line expressing five human cytochromes P-450 and microsomal epoxide hydrolase. Mutagenesis, 8: 363-372, 1993.
7. Crespi, C. L , Gonzales, F. J , Steimel, D. T , Turner, T. R., Gelboin, H. V., Periman, B W., and Langenbach, R. A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. Chem. Res. Toxicol., 4: 566-572, 1991.
8. Mani, C , and Kupfer, D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51: 6052-6058, 1991.
9. Pathak, D. N., and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis (Lond ), 15: 529-532, 1994.
10. Sargent, L. M , Dragan, V. P., Bahnub, H., Wiley, J E., Sattler, C. A., Schroeder, P , Sattler, G. L., Jordan, V. C., and Pitot, H. C. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res , 54: 3357-3360, 1994.
11. Vancutsem, P. L., Lazarus, P., and Williams, G. M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen Cancer Res., 54: 3864-3867, 1994.
12. Fisher, B., Costantino, J. P., Redmond, C K., Fisher, E. R., Wickerham, D. L., and Cronin, W. W. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst., 86: 527-537, 1994.
13. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W. W , Kiemeney, L. H. L. M., Gimbrere, C H. F , Otter, R , Schouten, I. J., Damhuis, R. A. M., Bortenbal, M., Diepenhorst, F. W., van den Belt-Dusebout, A. W., and van Tinteren, H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343: 448-452, 1994.
14. King, C M. Tamoxifen and the induction of cancer. Carcinogenesis (Lond ), 16: 11449-11454, 1995.
15. Phillips, D. H., Carmichael, P. L , Hewer, A., Cole, K J., and Poon, G. K α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54: 5518-5522, 1994.
16. Foster, A. B , Jarman, M., Leung, O-T., McCague, R., Leclercq, G., and Devleeschouwer, N. Hydroxy derivatives of tamoxifen. J. Med. Chem., 28. 1491-1497, 1985.
17. Schoket, B., Hewer, A., Grover, P. L., and Phillips, D. H. Formation of DNA adducts in human skin maintained in short-term organ culture and treated with coal-tar, creosote or bitumen. Int. J. Cancer, 42. 622-626, 1988
18. Gupta, R. C. Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc Natl. Acad. Sci USA, 81: 6943-6947, 1984.
19. Phillips, D. H , Hewer, A., White, I. N. H , and Farmer, P B Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats Carcinogenesis (Lond.), 15: 793-795, 1994.
20. 5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen Carcinogenesis (Lond.) 15: 1487-1492, 1994.
21. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R , Poon, G K., Keogh, A., and Strain, A. J. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis (Lond.), 17: 89-94, 1996.
22. Osborne, M R , Hewer, A., Hardcastle, I. R., Carmichael, P L , and Phillips, D. H Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56. 66-71, 1996.